Avalo Therapeutics, Inc.AVTXNASDAQ
Loading
Year-over-year net income growth rate
Percentile
P33
Within normal range
vs 3Y Ago
-0.4x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | -47.48% |
| Q2 2025 | -57.92% |
| Q1 2025 | 62.79% |
| Q4 2024 | -253.40% |
| Q3 2024 | -76.60% |
| Q2 2024 | 181.18% |
| Q1 2024 | -1384.94% |
| Q4 2023 | -56.24% |
| Q3 2023 | 36.19% |
| Q2 2023 | 17.70% |
| Q1 2023 | -1.46% |
| Q4 2022 | -407.39% |
| Q3 2022 | 124.58% |
| Q2 2022 | 41.10% |
| Q1 2022 | -14.87% |
| Q4 2021 | -10.35% |
| Q3 2021 | -1.70% |
| Q2 2021 | 44.25% |
| Q1 2021 | -96.13% |
| Q4 2020 | -16.23% |
| Q3 2020 | -1.34% |
| Q2 2020 | 37.11% |
| Q1 2020 | -1402.67% |
| Q4 2019 | 140.36% |
| Q3 2019 | 35.46% |
| Q2 2019 | 16.51% |
| Q1 2019 | -34.09% |
| Q4 2018 | 77.41% |
| Q3 2018 | -309.55% |
| Q2 2018 | -54.72% |
| Q1 2018 | -25.59% |
| Q4 2017 | -116.51% |
| Q3 2017 | 1140.89% |
| Q2 2017 | 8.27% |
| Q1 2017 | -19.62% |
| Q4 2016 | 73.43% |
| Q3 2016 | -75.04% |
| Q2 2016 | 31.44% |
| Q1 2016 | -40.90% |
| Q4 2015 | -427.87% |